Translation of anticancer efficacy from nonclinical models to the clinic

CPT: Pharmacometrics and Systems Pharmacology

Volumn 3, Issue 8, 2014, Pages

  Stroh, M ^a   Duda, D G ^b   Takimoto, C H ^c   Yamazaki, S ^d   Vicini, P ^d  

^a GENENTECH INC   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84906875146     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2014.28     Document Type: Review

References (10)

1. Kamb, A., Wee, S. & Lengauer, C. Why is cancer drug discovery so difficult? Nat. Rev. Drug Discov. 6, 115-120 (2007).
2. Jain, R.K. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J. Clin. Oncol. 31, 2205-2218 (2013).
3. Snuderl, M. et al. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell 152, 1065-1076 (2013).
4. Duda, D.G., Kozin, S.V., Kirkpatrick, N.D., Xu, L., Fukumura, D. & Jain, R.K. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin. Cancer Res. 17, 2074-2080 (2011).
5. Goulart, B.H., Clark, J.W., Pien, H.H., Roberts, T.G., Finkelstein, S.N. & Chabner, B.A. Trends in the use and role of biomarkers in phase I oncology trials. Clin. Cancer Res. 13, 6719-6726 (2007).
6. Workman, P. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol. Cancer Ther. 2, 131-138 (2003).
7. Plummer, R. et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 14, 7917-7923 (2008).
8. Dowlati, A. et al. Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416. Clin. Cancer Res. 11, 7938-7944 (2005).
9. Wang, S., Guo, P., Wang, X., Zhou, Q. & Gallo, J.M. Preclinical pharmacokinetic/ pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models. Mol. Cancer Ther. 7, 407-417 (2008).
10. Yamazaki, S. Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib. AAPS J. 15, 354-366 (2013).